Alaunos closes registered direct offering, gross proceeds about $1.12 million

Alaunos Therapeutics, Inc. (Nasdaq: TCRT) entered into a securities purchase agreement on September 18, 2026 for a registered direct offering. Under the agreement, the company agreed to sell and issue 380,469 shares of common stock at $1.46 per share, and 386,654 pre-funded warrants at a purchase price of $1.459 per pre-funded warrant.¹

The press release described the deal as generating aggregate gross proceeds of approximately $1,120,000, before deducting placement agent fees and offering expenses.¹ The offering closed on September 21, 2026, and the company received net proceeds of approximately $915,400.50, after deducting estimated offering expenses payable by the company, including placement agent fees.¹

The two company documents describe the underlying registration statement differently. The 8-K states the offering was made under a Registration Statement on Form S-3, as amended, File No. 333-289748, which was filed on November 7, 2025, and became effective on November 27, 2025.¹ The press release, however, describes the same registration statement as an effective shelf registration statement on Form S-3, File No. 333-289748, initially filed with the SEC on November 11, 2025 and effective on December 1, 2025.¹

The company said it intends to use the net proceeds from the offering for general corporate purposes, including working capital.¹ Dawson James Securities, Inc. acted as exclusive placement agent and was paid a cash fee of 8% of the aggregate gross proceeds, plus reimbursed expenses.¹ Company officers and directors also agreed to a 15-day lock-up period following the offering, restricting sales or transfers of company stock, subject to certain exceptions.¹